Subtype
Malignant Urinary Tract Neoplasm
CI-CAN-00003252Explore in graph →
507 active trials14 approved drugs29 evidence items
- NCIt
- C192668
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003252Explore in graph →
Clinical trials
1,954 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (246)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT02901548 | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | terminated | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT01732107 | Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression | terminated | Phase 2 | 13 | Noah Hahn, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT03549650 | Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms | terminated | Phase 2 | 3 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT01126749 | Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer | terminated | Phase 1 / Phase 2 | 92 | Eisai Inc.INDUSTRY | 6 | Feb 28, 2022 | clinicaltrials |
| NCT01093066 | Prospective Multicentric Evaluation of a Bladder Preservation Strategy(ReChiVe) | terminated | Phase 2 | 77 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT03287050 | Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma | terminated | Phase 2 | 6 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02792192 | Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants | terminated | Phase 1 / Phase 2 | 24 | Hoffmann-La RocheINDUSTRY | 1 | Oct 28, 2021 | clinicaltrials |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04066595 | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.(CabUC) | terminated | Phase 2 | 7 | Johannes Gutenberg University MainzOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy | terminated | Phase 2 | 140 | Latin American Cooperative Oncology GroupOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT02693717 | Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2021 | clinicaltrials |
| NCT01438112 | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer(BOND) | terminated | Phase 2 / Phase 3 | 22 | CG Oncology, Inc.INDUSTRY | 1 | Apr 14, 2021 | clinicaltrials |
| NCT03498196 | A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer | terminated | Phase 1 / Phase 2 | 1 | Baylor College of MedicineOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT03719300 | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC | terminated | Phase 2 | 32 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Aug 19, 2020 | clinicaltrials |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | terminated | Phase 1 / Phase 2 | 6 | University of OxfordOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02169284 | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02010203 | A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT | terminated | Phase 1 / Phase 2 | 104 | Heat BiologicsINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01094496 | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) | terminated | Phase 2 | 3 | Celldex TherapeuticsINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT01611662 | Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | terminated | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01118351 | Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer | terminated | Phase 2 | 19 | Case Comprehensive Cancer CenterOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT02334527 | Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy | terminated | Phase 2 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT02605863 | Enzalutamide for Bladder Cancer Chemoprevention | terminated | Phase 2 | 1 | University of RochesterOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00089128 | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | terminated | Phase 2 | 16 | Medical University of South CarolinaOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT00268450 | Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | terminated | Phase 2 | 21 | Medical University of South CarolinaOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT01331824 | Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma | terminated | Phase 2 | 22 | Matthew GalskyOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT01234519 | A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy | terminated | Phase 1 / Phase 2 | 12 | AEterna ZentarisINDUSTRY | 1 | Mar 15, 2018 | clinicaltrials |
| NCT00003452 | Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder | terminated | Phase 2 | 4 | Burzynski Research InstituteOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT01622660 | Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT01042795 | Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy | terminated | Phase 2 | 7 | University of MichiganOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT01353222 | DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | terminated | Phase 2 | 142 | DendreonINDUSTRY | 1 | May 25, 2017 | clinicaltrials |
| NCT01475266 | Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) | terminated | Phase 2 / Phase 3 | 51 | Nippon Kayaku Co., Ltd.INDUSTRY | 2 | Mar 29, 2017 | clinicaltrials |
| NCT02030574 | Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin | terminated | Phase 2 | 2 | Brown UniversityOTHER | 1 | Aug 24, 2016 | clinicaltrials |
| NCT00022633 | S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract | terminated | Phase 2 | 65 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 11, 2016 | clinicaltrials |
| NCT01339000 | Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2) | terminated | Phase 2 | 73 | BIND TherapeuticsINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT01916109 | Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | terminated | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT01663285 | Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) | terminated | Phase 2 | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00714948 | Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 16, 2015 | clinicaltrials |
| NCT00479089 | Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | terminated | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT00635726 | Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer | terminated | Phase 2 | 41 | Hellenic Oncology Research GroupOTHER | 1 | Oct 8, 2015 | clinicaltrials |
| NCT00995488 | Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer | terminated | Phase 2 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 11, 2015 | clinicaltrials |
| NCT01374789 | PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer(PURO) | terminated | Phase 2 | 2 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00933374 | Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma(RAD001) | terminated | Phase 2 | 28 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Mar 18, 2015 | clinicaltrials |
| NCT00393796 | Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma | terminated | Phase 2 | 54 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 13, 2014 | clinicaltrials |
| NCT02013765 | A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer | terminated | Phase 2 | 5 | Hoffmann-La RocheINDUSTRY | 1 | Sep 25, 2014 | clinicaltrials |
| NCT00112905 | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Dec 9, 2022source: clinicaltrials